Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06299410
PHASE1

PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects

Sponsor: Intra-Cellular Therapies, Inc.

View on ClinicalTrials.gov

Summary

The study will be conducted as an open-label and single-center study to evaluate the occupancy of ITI-1284 to the dopamine D2 receptor, serotonin 2A (5-HT2A) receptor, and serotonin transporter (SERT) in healthy subjects.

Official title: An Open-label, Positron Emission Tomography Study to Evaluate Brain Receptor Occupancy, Safety, Tolerability, and Pharmacokinetics After a Single Sublingual Administration of ITI-1284 in Healthy Subjects

Key Details

Gender

All

Age Range

18 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2024-04-11

Completion Date

2025-09

Last Updated

2025-01-28

Healthy Volunteers

Yes

Interventions

DRUG

ITI-1284 10 mg

ITI-1284 tablet

DRUG

ITI-1284 20 mg

ITI-1284 tablet

Locations (1)

Clinical Site 1

New Haven, Connecticut, United States